Key points from article :
Biolinq, a California-based health tech company, has secured $100 million in Series C venture funding to bring its innovative glucose-sensing patch closer to commercial launch. The small, wearable device—about the size of a coin—is designed to monitor glucose levels without the need for needles, offering a less invasive alternative for people with Type 2 diabetes who don’t use insulin.
Unlike traditional continuous glucose monitors, Biolinq’s sensor sits on the skin and uses a network of electrochemical sensors to measure biomarkers like glucose, lactate, and ketones. It avoids penetrating deeply into tissue and instead collects data from just beneath the skin's surface. The patch also includes features to monitor sleep and physical activity, and displays real-time blood sugar feedback through a colour-changing light.
Chairman Dan Bradbury described the product as a step toward more accessible and simplified health tracking for millions managing metabolic conditions. The funding, led by Alpha Wave Ventures, will support final development, regulatory submissions in the U.S., and preparation for commercial rollout. Biolinq has now raised over $250 million, including a $58 million round in 2024 and a $100 million Series B in 2021.
